Adicet Bio Q2 FY26 net loss widens to $21.4 million; cash and short-term investments total $118.2 million
Reuters2026/08/05 21:23- Adicet Bio posted a net loss of $21.4 million, or $1.99 per share, for the second quarter ended June 30, 2026.
- R&D expense totaled $18.5 million; G&A expense was $3.9 million.
- Cash, cash equivalents and short-term investments were $118.2 million; funding runway expected into the second half of 2027.
- Phase 1 prula-cel update in lupus nephritis and SLE is now expected in 3Q 2026, with topline results anticipated in 3Q 2026.
- Regulatory filing for ADI-212 in mCRPC targeted for 3Q 2026, with Phase 1 enrollment expected to begin in 4Q 2026 pending clearance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
For the first time in over a year, the open interest share of altcoins has surpassed that of bitcoin.
OPEC+ agrees to keep oil output policy unchanged for October
US military strikes Iranian oil tanker, triggering geopolitical risks as Brent crude nears $97 mark
Following the US military's attack on Iranian oil tankers and Iran's announcement of new restricted navigation zones outside the Strait of Hormuz, market concerns over prolonged disruptions in key energy transport routes have intensified, leading to a sharp rise in international oil prices.
Geopolitical tensions overshadowing production cuts: OPEC+ maintains quotas unchanged, paper adjustments fail to resolve physical supply dilemmas
OPEC+ major oil producers, led by Saudi Arabia and Russia, held a monthly video conference last Sunday and decided to keep the crude oil production quota for October unchanged, continuing the previous tone of stable production following a series of symbolic production increases.
Crypto prices
More
